ClearVue Technologies Reports Expiry of 93,333 Options at $0.75 Exercise Price

Details on the Expiry of 93,333 CPVAS Options at $0.75

The expired securities were classified under ASX code CPVAS, representing options expiring 19 June 2026 with a $0.75 exercise price per share. According to the company update, these 93,333 options lapsed on 19 June 2026 without being exercised or converted into ordinary shares. The cessation reason is recorded as "expiry of option or other convertible security without exercise or conversion."

The lack of exercise indicates holders did not find it economically beneficial to convert these options, likely because the exercise price of $0.75 exceeded the prevailing share price at expiry. ClearVue confirmed no consideration was paid in relation to this cessation, and no further details were provided beyond the required disclosure. The immediate impact on the share price was not evident from publicly available information.

Ordinary Share Count Remains at 349,335,180

Because the CPVAS options expired unexercised, no new ordinary shares were issued. The total number of fully paid ordinary shares remains at 349,335,180, as shown in Part 3 of the Appendix 3H lodged with ASX. This figure forms the basis for ClearVue’s market capitalisation calculation at any given time.

For shareholders and potential investors, the unchanged share count reflects a routine capital management event where out-of-the-money options expire without dilution. The CPVAS option class now shows zero securities on issue and is removed from the company’s active capital structure.

Overview of ClearVue’s Remaining Unquoted Option Classes

Following the expiry of CPVAS options, ClearVue’s unquoted equity securities include several option tranches with varying expiry dates and exercise prices. The largest tranche is CPVAU, consisting of 25,689,625 options expiring 1 September 2026 at $0.20. Other notable tranches include 4,000,000 options under CPVAV expiring 20 February 2029 at $0.30, and 989,550 options under CPVAW expiring 20 February 2028 at $0.27.

Additional unquoted options include 2,000,000 options under CPVAP expiring 13 December 2026 at $0.50, 2,000,000 under CPVAQ expiring 13 December 2026 at $1.00, 3,000,000 under CPVAM expiring 30 November 2026 at $0.50, 1,150,000 under CPVAT expiring 30 June 2027 at $0.549, and 500,000 under CPVAO expiring 30 October 2027 with no exercise price. Collectively, these options represent potential future shares that could be issued if exercised, making the option schedule important for investors assessing dilution risk.

Outstanding 14,000,000 Performance Rights Under CPVAH

In addition to options, ClearVue has 14,000,000 performance rights outstanding, listed under ASX code CPVAH. Unlike options with fixed exercise prices, performance rights typically vest and convert to ordinary shares upon meeting specified milestones, performance targets, or time-based conditions.

The company update does not detail the vesting conditions, expiry dates, or milestones related to the CPVAH performance rights. Investors seeking detailed terms should consult prior disclosures such as Appendix 3G filings or remuneration reports where these rights were originally described. The announcement did not provide further information on these specifics.

Upcoming Expiry of CPVAU Options in September 2026

With the CPVAS options expired, investor focus is likely to shift to the next major expiry: the CPVAU tranche of 25,689,625 options at $0.20 exercise price, expiring on 1 September 2026—less than two months from the update date. This is the largest remaining option class by volume.

If holders exercise these options before expiry, ClearVue would receive proceeds of $0.20 per option exercised, and the issued share count would increase accordingly. Conversely, if they lapse unexercised—as with CPVAS—no new shares would be issued and no funds received. The CPVAU expiry represents a significant near-term event for the company’s capital structure.

Significance of Unexercised $0.75 Options

The expiration of CPVAS options at $0.75 without any exercise suggests ClearVue’s share price did not reach levels making exercise financially attractive. Typically, options are exercised when the market price exceeds the exercise price, providing immediate value to holders.

This outcome aligns with challenges faced by many small-cap ASX-listed technology firms amid changing investor sentiment and sector valuations. ClearVue provided no commentary on the expiry circumstances or share price outlook, limiting conclusions to the disclosed facts.

Implications of Updated Capital Structure on Dilution

Post-expiry, ClearVue maintains 349,335,180 ordinary shares alongside a significant pool of unquoted options and performance rights. Should all remaining options—including CPVAU, CPVAV, CPVAW, CPVAO, CPVAP, CPVAQ, CPVAT, and CPVAM—be exercised, the total dilution could materially increase the share count. The aggregate outstanding options number approximately 39,329,175, excluding the 14,000,000 performance rights.

Equity-linked securities dilution is a common consideration for investors in early-stage technology companies, where options serve as capital raising and incentive tools. The removal of the CPVAS class slightly simplifies ClearVue’s capital structure, but the large CPVAU tranche expiring soon remains a key factor for shareholders to monitor.

Appendix 3H Filing and Compliance

Filing an Appendix 3H form is a mandatory ASX requirement when securities cease through expiry, cancellation, or conversion. By lodging this form on 1 July 2026, ClearVue fulfills its continuous disclosure obligations, keeping the market informed of changes to its issued capital.

The update notes the issued capital figures are system-generated and may not reflect concurrent changes being processed by ASX. This standard disclaimer does not indicate any irregularity. The filing complies with ASX disclosure standards.

About ClearVue Technologies and Its Transparent Solar Glass Innovation

ClearVue Technologies is an Australian company developing and commercializing transparent solar energy glass technology that integrates photovoltaic cells into building materials like windows and glazing panels. This innovation enables buildings to generate solar power from facades without compromising transparency or aesthetics, targeting the growing market for building-integrated photovoltaics.

Investors and analysts remain interested in ClearVue’s commercial progress, partnerships, and revenue prospects within the clean energy sector. While this update concerns a routine capital event, it offers insight into the company’s evolving share structure as it advances commercialization. The forthcoming CPVAU option expiry on 1 September 2026 is the next significant capital management milestone.